Journal of Chinese Integrative Medicine ›› 2009, Vol. 7 ›› Issue (10): 976-982.doi: 10.3736/jcim20091012
• Literature Review • Previous Articles Next Articles
Gastroretentive floating drug delivery systems with potential herbal drugs for Helicobacter pylori eradication: A review
Shreeraj H. Shaha
,Jayvadan K. Pab,Nieltrav V. Patelc
- a Department of Pharmaceutics, Lok Jagruti Institute of Pharmacy, Gujarat University, Ahmedabad 382 210, Gujarat, India
b Department of Pharmaceutics, Nootan Pharmacy College, North Gujarat Hemchandracharya University, Visnagar 384 315, North Gujarat, India
c Department of Pharmaceutics, Anand College of Pharmacy, Sardar Patel University, Anand 388 001, Gujarat, India
| [1] | Andreica V, Sandica-Andreica B, Draghici A, Chiorean E, Georoceanu A, Rusu M . The prevalence of anti-Helicobacter pylori antibodies in the patients with ischemic heart disease[J]. Rom J Intern Med, 2004,42(1):183-189 |
| [2] |
Morgner A, Bayerdorffer E, Neubauer A, Stolte M . Malignant tumors of the stomach. Gastric mucosa-associated lymphoid tissue lymphoma and Helicobacter pylori[J]. Gastroenterol Clin North Am, 2000,29(3):593-607
doi: 10.1016/S0889-8553(05)70132-1 |
| [3] |
Kawahara Y, Mizuno M, Yoshino T, Yokota K, Oguma K, Okada H, Fujiki S, Shiratori Y . HLA-DQA1*0103-DQB1*0601 haplotype and Helicobacter pylori-positive gastric mucosa-associated lymphoid tissue lymphoma[J]. Clin Gastroenterol Hepatol, 2005,3(9):865-868
doi: 10.1016/S1542-3565(05)00185-0 |
| [4] |
Marshall B . Helicobacter pylori: 20 years on[J]. Clin Med, 2002,2(2):147-152
doi: 10.7861/clinmedicine.2-2-147 pmid: 11991099 |
| [5] |
Suzuki H, Ishii H . Role of apoptosis in Helicobacter pylori-associated gastric mucosal injury[J]. J Gastroenterol Hepatol, 2000,15(Suppl):D46-D54
doi: 10.1046/j.1440-1746.2000.02147.x pmid: 10759220 |
| [6] |
Lehmann FS, Terracciano L, Carena I, Baeriswyl C, Drewe J, Tornillo L, De Libero G, Beglinger C . In situ correlation of cytokine secretion and apoptosis in Helicobacter pylori-associated gastritis[J]. Am J Physiol Gastrointest Liver Physiol, 2002,283(2):G481-G488
doi: 10.1152/ajpgi.00422.2001 |
| [7] |
Papini E, Zoratti M, Cover TL . In search of the Helicobacter pylori VacA mechanism of action[J]. Toxicon, 2001,39(11):1757-1767
doi: 10.1016/S0041-0101(01)00162-3 pmid: 11595638 |
| [8] |
Blanchard TG, Drakes ML, Czinn SJ . Helicobacter infection: pathogenesis[J]. Curr Opin Gastroenterol, 2004,20(1):10-15
doi: 10.1097/00001574-200401000-00004 |
| [9] |
Atherton JC . The pathogenesis of Helicobacter pylori-induced gastro-duodenal diseases[J]. Annu Rev Pathol, 2006,( 1):63-96
doi: 10.1146/annurev.pathol.1.110304.100125 pmid: 18039108 |
| [10] |
Iijima K, Sekine H, Koike T, Imatani A, Ohara S, Shimosegawa T . Long-term effect of Helicobacter pylori eradication on the reversibility of acid secretion in profound hypochlorhydria[J]. Aliment Pharmacol Ther, 2004,19(11):1181-1188
doi: 10.1111/apt.2004.19.issue-11 |
| [11] |
Chang FY, Lu CL, Chen CY, Luo JC, Jium KL, Lee SD . Effect of Helicobacter pylori eradicated therapy on water gastric emptying in patients with active duodenal ulcer[J]. J Gastroenterol Hepatol, 2003,18(11):1250-1256
doi: 10.1046/j.1440-1746.2003.03168.x |
| [12] | Uygun A, Kadayifci A, Yesilova Z, Ates Y, Safali M, Ilgan S, Bagci S, Dagalp K . Poor efficacy of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori eradication[J]. Indian J Gastroenterol, 2007,26(4):174-177 |
| [13] | Batchelor H, Conway B, Williams RO. Targeting the infections within the gastrointestinal tract. In: Williams RO, Taft DR, McConville JT. Advanced drug formulation design to optimize therapeutic outcomes (Drugs and the pharmaceutical sciences). New York: Informa Healthcare. 2007: 217-244. |
| [14] |
Lahaie R, Farley A, Dallaire C, Archambault A, Fallone CA, Ponich T, Hunt R, Oravec M, Whitsitt P, Van Zanten SV, Marcon N, Bailey R, Dumont A, Nguyen B, Desrochers S, Spénard J . Bismuth-based quadruple therapy with bismuth subcitrate, metronidazole, tetracycline and omeprazole in the eradication of Helicobacter pylori[J]. Can J Gastroenterol, 2001,15(9):581-585
doi: 10.1155/2001/305756 |
| [15] |
De Boer WA . A novel therapeutic approach for Helicobacter pylori infection: the bismuth-based triple therapy monocapsule[J]. Expert Opin Investig Drugs, 2001,10(8):1559-1566
doi: 10.1517/13543784.10.8.1559 |
| [16] |
Kato M, Yamaoka Y, Kim JJ, Reddy R, Asaka M, Kashima K, Osato MS, El-Zaatari FA, Graham DY, Kwon DH . Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan[J]. Antimicrob Agents Chemother, 2000,44(8):2214-2216
doi: 10.1128/AAC.44.8.2214-2216.2000 |
| [17] |
Streubel A, Siepmann J, Bodmeier R . Multiple unit gastroretentive drug delivery systems: a new preparation method for low density microparticles[J]. J Microencapsul, 2003,20(3):329-347
doi: 10.3109/02652040309178073 |
| [18] | Bernier JJ , Adrian V.Les aliments dans le tube digestif[M]. Paris: Doin Editions, 1988 11-24 |
| [19] | Dubernet C. Systèmes a libération gastrique prolongée. In: Falson-Rieg F, Faivre V, Pirot F.Nouvelles formes médicamenteuses. Paris: Médicales Internationales, Lavoisier. 2004: 119-133. |
| [20] | Dressman JB, Lennernas H.Oral drug absorption: prediction and assessment[M]. New York: Marcel Dekker , 2000 1-10 |
| [21] |
Reddy LH, Murthy RS . Floating dosage systems in drug delivery[J]. Crit Rev Ther Drug Carrier Syst, 2002,19(6):553-585
doi: 10.1615/CritRevTherDrugCarrierSyst.v19.i6.20 pmid: 12822735 |
| [22] |
Hwang SJ, Park H, Park K . Gastric retentive drug-delivery systems[J]. Crit Rev Ther Drug Carrier Syst, 1998,15(3):243-284
doi: 10.1615/CritRevTherDrugCarrierSyst.v15.i3.20 pmid: 9699081 |
| [23] |
Erni W, Held K . The hydrodynamically balanced system: a novel principle of controlled drug release[J]. Eur Neurol, 1987,27(Suppl 1):21-27
doi: 10.1159/000116171 pmid: 3322836 |
| [24] |
Koller WC, Pahwa R . Treating motor fluctuations with controlled-release levodopa preparations[J]. Neurology, 1994,44(7 Suppl 6):S23-S28
doi: 10.1159/000110377 pmid: 8047257 |
| [25] |
Kawashima Y, Niwa T, Takeuchi H, Hino T, Itoh Y . Hollow microspheres for use as a floating controlled drug delivery system in the stomach[J]. J Pharm Sci, 1992,81(2):135-140
doi: 10.1002/jps.2600810207 pmid: 1372046 |
| [26] |
Streubel A, Siepmann J, Bodmeier R . Floating microparticles based on low density foam powder[J]. Int J Pharm, 2002,241(2):279-292
doi: 10.1016/S0378-5173(02)00241-7 pmid: 12100855 |
| [27] |
Talukder R, Fassihi R . Gastroretentive delivery systems: hollow beads[J]. Drug Dev Ind Pharm, 2004,30(4):405-412
doi: 10.1081/DDC-120030935 pmid: 15132183 |
| [28] |
Murata Y, Sasaki N, Miyamoto E, Kawashima S . Use of floating alginate gel beads for stomach-specific drug delivery[J]. Eur J Pharm Biopharm, 2000,50(2):221-226
doi: 10.1016/S0939-6411(00)00110-7 |
| [29] |
Whitehead L, Fell JT, Collett JH . Development of a gastroretentive dosage form[J]. Eur J Pharm Sci, 1996,4(Suppl 1):S182
doi: 10.1016/S0928-0987(97)86558-X |
| [30] |
Umamaheshwari RB, Jain S, Bhadra D, Jain NK . Floating microspheres bearing acetohydroxamic acid for the treatment of Helicobacter pylori[J]. J Pharm Pharmacol, 2003,55(12):1607-1613
doi: 10.1211/0022357022223 |
| [31] |
Umamaheswari RB, Jain S, Tripathi PK, Agrawal GP, Jain NK . Floating-bioadhesive microspheres containing acetohydroxamic acid for clearance of Helicobacter pylori[J]. Drug Deliv, 2002,9(4):223-231
doi: 10.1080/10717540260397837 |
| [32] | Akhtar H, Virmani OP, Popli SP, Misra LN, Gupta MM, Srivastava GN, Abraham Z, Singh AK.Diction-ary of Indian medicinal plants[M]. Lucknow: Central Institute of Medicinal and Aromatic Plants , 1992 458 |
| [33] | Inamdar MC, Rajarama Rao MR . Studies on the pharmacology of Terminalia chebula[J]. J Sci Ind Res, 1962,( 21C):345-348 |
| [34] |
Sato Y, Oketani H, Singyouchi K, Ohtesuro T, Kihara M, Shibata H, Higuti T . Extraction and purification of effective antimicrobial constituents of Terminalia chebula RETS. against methicillin-resistance Staphylococcus aureus[J]. Biol Pharm Bull, 1997,20(4):401-404
doi: 10.1248/bpb.20.401 |
| [35] |
Malekzadeh F, Ehsanifar H, Shahamat M, Levin M, Colwell RR . Antibacterial activity of black myrobalan(Terminalia chebula Retz) against Helicobacter pylori[J]. Int J Antimicrob Agents, 2001,18(1):85-88
doi: 10.1016/S0924-8579(01)00352-1 |
| [36] |
Shukla Y, Kalra N . Cancer chemoprevention with garlic and its constituents[J]. Cancer Lett, 2007,247(2):167-181
doi: 10.1016/j.canlet.2006.05.009 pmid: 16793203 |
| [37] | Presser A.Pharmacists's guide to medicinal herbs[M]. Petaluma, CA: Smart Publications , 2000, 147-154 |
| [38] | Mahady GB, Pendland SL, Yun GS, Lu ZZ, Stoia A . Ginger(Zingiber officinale Roscoe) and the gingerols inhibit the growth of CagA+ strains of Helicobacter pylori[J]. Anticancer Res, 2003,23(5A):3699-3702 |
| [39] | Mahady GB, Pendland SL, Yun G, Lu ZZ . Turmeric(Curcuma longa) and curcumin inhibit the growth of Helicobacter pylori, a group 1 carcinogen[J]. Anticancer Res, 2002,22(6C):4179-4181 |
| [40] |
Nostro A, Cellini L, Di Bartolomeo S, Di Campli E, Grande R, Cannatelli MA, Marzio L, Alonzo V . Antibacterial effect of plant extracts against Helicobacter pylori[J]. Phytother Res, 2005,19(3):198-202
doi: 10.1002/ptr.1640 pmid: 15934015 |
| [41] |
Foryst-Ludwig A, Neumann M, Schneider-Brachert W, Naumann M . Curcumin blocks NF-kappaB and the motogenic response in Helicobacter pylori-infected epithe-lial cells[J]. Biochem Biophys Res Commun, 2004,316(4):1065-1072
doi: 10.1016/j.bbrc.2004.02.158 |
| [42] |
Smith-Palmer A, Stewart J, Fyfe L . Antimicrobial properties of plant essential oils and essences against five important food-borne pathogens[J]. Lett Appl Microbiol, 1998,26(2):118-122
doi: 10.1046/j.1472-765X.1998.00303.x |
| [43] |
Krausse R, Bielenberg J, Blaschek W, Ullmann U . In vitro anti-Helicobacter pylori activity of Extractum liquiritiae, glycyrrhizin and its metabolites[J]. J Antimicrob Chemother, 2004,54(1):243-246
doi: 10.1093/jac/dkh287 |
| [44] |
Fukai T, Marumo A, Kaitou K, Kanda T, Terada S, Nomura T . Anti-Helicobacter pylori flavonoids from licorice extract[J]. Life Sci, 2002,71(12):1449-1463
doi: 10.1016/S0024-3205(02)01864-7 pmid: 12127165 |
| [45] |
Mahady GB, Pendland SL, Stoia A, Chadwick LR . In vitro susceptibility of Helicobacter pylori to isoquinoline alkaloids from Sanguinaria canadensis and Hydrastis canadensis[J]. Phytother Res, 2003,17(3):217-221
doi: 10.1002/(ISSN)1099-1573 |
| [46] | Higuchi K, Arakawa T, Ando K, Fujiwara Y, Uchida T, Kuroki T . Eradication of Helicobacter pylori with a Chinese herbal medicine without emergence of resistant colonies[J]. Am J Gastroenterol, 1999,94(5):1419-1420 |
| [47] | Zhang L, Yang LW, Yang LJ, Zheng XG , Pan CL.Relation between Helicobacter pylori and pathogenesis of chronic atrophic gastritis and the research of its prevention and treatment[J]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 1992, 12(9):521-523, 515-516 |
| 张琳, 杨连文, 杨李君, 郑晓光, 潘崇兰 . 幽门螺旋菌与慢性萎缩性胃炎发病关系及防治研究[J].中国中西医结合杂志, 1992, 12(9):521-523, 515-516 |